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Summary
Background Numerous population-based studies of age-related macular degeneration have been reported around the 
world, with the results of some studies suggesting racial or ethnic diﬀ erences in disease prevalence. Integrating these 
resources to provide summarised data to establish worldwide prevalence and to project the number of people with 
age-related macular degeneration from 2020 to 2040 would be a useful guide for global strategies.
Methods We did a systematic literature review to identify all population-based studies of age-related macular 
degeneration published before May, 2013. Only studies using retinal photographs and standardised grading 
classiﬁ cations (the Wisconsin age-related maculopathy grading system, the international classiﬁ cation for age-related 
macular degeneration, or the Rotterdam staging system) were included. Hierarchical Bayesian approaches were used 
to estimate the pooled prevalence, the 95% credible intervals (CrI), and to examine the diﬀ erence in prevalence by 
ethnicity (European, African, Hispanic, Asian) and region (Africa, Asia, Europe, Latin America and the Caribbean, 
North America, and Oceania). UN World Population Prospects were used to project the number of people aﬀ ected in 
2014 and 2040. Bayes factor was calculated as a measure of statistical evidence, with a score above three indicating 
substantial evidence.
Findings Analysis of 129 664 individuals (aged 30–97 years), with 12 727 cases from 39 studies, showed the pooled 
prevalence (mapped to an age range of 45–85 years) of early, late, and any age-related macular degeneration to be 
8·01% (95% CrI 3·98–15·49), 0·37% (0·18–0·77), and 8·69% (4·26–17·40), respectively. We found a higher 
prevalence of early and any age-related macular degeneration in Europeans than in Asians (early: 11·2% vs 6·8%, 
Bayes factor 3·9; any: 12·3% vs 7·4%, Bayes factor 4·3), and early, late, and any age-related macular degeneration to 
be more prevalent in Europeans than in Africans (early: 11·2% vs 7·1%, Bayes factor 12·2; late: 0·5% vs 0·3%, 3·7; 
any: 12·3% vs 7·5%, 31·3). There was no diﬀ erence in prevalence between Asians and Africans (all Bayes factors <1). 
Europeans had a higher prevalence of geographic atrophy subtype (1·11%, 95% CrI 0·53–2·08) than Africans (0·14%, 
0·04–0·45), Asians (0·21%, 0·04–0·87), and Hispanics (0·16%, 0·05–0·46). Between geographical regions, cases of 
early and any age-related macular degeneration were less prevalent in Asia than in Europe and North America (early: 
6·3% vs 14.3% and 12·8% [Bayes factor 2·3 and 7·6]; any: 6·9% vs 18·3% and 14·3% [3·0 and 3·8]). No signiﬁ cant 
gender eﬀ ect was noted in prevalence (Bayes factor <1·0). The projected number of people with age-related macular 
degeneration in 2020 is 196 million (95% CrI 140–261), increasing to 288 million in 2040 (205–399).
Interpretation These estimates indicate the substantial global burden of age-related macular degeneration. 
Summarised data provide information for understanding the eﬀ ect of the condition and provide data towards 
designing eye-care strategies and health services around the world.
Funding National Medical Research Council, Singapore.
Introduction
Age-related macular degeneration accounts for 8·7% of 
all blindness worldwide and is the most common cause 
of blindness in developed countries,1–5 particularly in 
people older than 60 years. Its prevalence is likely to 
increase as a consequence of exponential population 
ageing. There have been signiﬁ cant advances in the 
management of exudative or so-called wet age-related 
macular degeneration with the introduction of anti-
angiogenesis therapy, and patients now have eﬀ ective 
treatment options that can prevent blindness and, in 
many cases, restore vision.6–10 However, these treatments 
are expensive and not available to all patients in many 
countries.11–14 Thus, understanding the prevalence, 
burden, and population impact is essential for adequate 
health care planning and provision, which require 
both precise and contemporary estimates of disease 
prevalence.
Although there have been many population-based 
studies of age-related macular degeneration around the 
world, there are no summarised data to guide global 
strategies. Furthermore, studies have suggested 
substantial racial or ethnic diﬀ erences in disease 
prevalence. In the Baltimore Eye Study, people of 
European (white) ancestry were more likely to have early 
and late-stage disease than were those of African 
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ancestry.15,16 Two meta-analyses done in populations of 
European17 and Asian ancestry4 suggest that, in people 
aged 40–79 years, the age-speciﬁ c prevalence of late age-
related macular degeneration in Asians (0·56%) was 
similar to that in Europeans (0·59%), but early signs 
were less common in Asians (6·8%) than in Europeans 
(8·8%). No studies had systematically compared the 
prevalence of the condition across geographical regions.
To address this gap, we did a systematic review of the 
literature to estimate the prevalence of age-related 
macular degeneration, and assess diﬀ erences by 
ethnicity, region, and sex, and to project the number of 
individuals aﬀ ected worldwide by the condition in 
2020 and 2040.
Methods
Search strategy
We systematically reviewed publications that reported 
prevalence of age-related macular degeneration by 
searching the electronic databases of PubMed, Web of 
Science, and Embase for relevant papers published up to 
May, 2013, with the following search terms (formatted for 
PubMed search): (“Macular Degeneration”[Mesh] AND 
(“Prevalence”[Mesh] OR “Epidemiology”[Mesh] OR 
“Cross-Sectional Studies” [Mesh] OR “Cohort 
Studies”[Mesh])); ((“age-related maculopathy”[All Fields] 
OR “age-related maculopathy”[All Fields] OR “age-related 
macular degeneration”[All Fields] OR “age related 
macular degeneration”[All Fields] OR “macular degen-
eration”[All Fields]) AND (“prevalence”[All Fields] OR 
“incidence”[All Fields] OR “epidemiology”[All Fields] OR 
“risk factors”[All Fields])).
The strategy identiﬁ ed all articles used in previous 
reviews.4,17 Reference lists of identiﬁ ed reports were also 
scanned to identify other relevant studies. The initial 
search was scrutinised in detail by clinician scientist XS 
and reviewed by senior clinician scientist C-YC. Data 
were checked by statisticians (WLW, XL). Disagreements 
were resolved by discussion.
Inclusion and exclusion criteria
Our meta-analysis was done according to the Meta-
analysis Of Observational Studies in Epidemiology 
(MOOSE) guidelines.18 The full texts of potentially 
relevant articles were reviewed to identify studies that 
met the inclusion and exclusion criteria. The two criteria 
for inclusion were: a population-based study from a 
deﬁ ned geographic area; and a standardised photographic 
assessment of age-related macular degeneration.
Population-based studies were included if they 
quantiﬁ ed the prevalence (including early, late, and 
exudative or neovascular age-related macular 
degeneration, and geographic atrophy) in population-
based samples, with clearly deﬁ ned methods of sampling. 
A response rate of 50% or higher was considered 
adequate for inclusion,19 with the exception of the 
European Eye Study (EUREYE) study20 since it was a 
large population study (45%); sensitivity analysis showed 
almost no eﬀ ect on our robust model estimates (appendix 
p 9). Surveys or audits of hospital eye departments or 
clinics were excluded. Studies inviting non-speciﬁ c 
volunteers or particular professions were excluded, as 
were studies that relied on self-reported diagnoses or did 
fundus examinations only in those with reduced vision.
For the standardised photographic assessment, we 
included studies that had used retinal photography and 
standardised grading methods to diagnose and classify 
lesions (ie, grading of retinal photographs following 
either the Wisconsin age-related maculopathy grading 
system,21 the international classiﬁ cation for age-related 
macular degeneration,22 or the Rotterdam staging 
system23) with reproducible grading results.
Studies fulﬁ lling any one of the following were 
excluded: use of only clinical examination by 
ophthalmoscopy or slit-lamp biomicroscopy for diagnosis 
(ie, lack of any grading reproducibility assessment); 
reports of number of eyes with age-related macular 
degeneration as opposed to the number of individuals; 
studies in which determination of prevalence was not 
one of the primary study objectives (eg, studies 
determining risk factors); and studies not population-
based, but were interview-based or audits of hospital eye 
departments. Although we did not speciﬁ cally exclude 
non-English literature, the studies included in the ﬁ nal 
analysis were all in English.
The classiﬁ cation systems used to deﬁ ne those with 
early, late, and any age-related macular degeneration 
(geographic atrophy and neovascular age-related macular 
degeneration) in each study were recorded with the 
Wisconsin age-related maculopathy grading system21 or 
the international classiﬁ cation.22 Early disease was 
deﬁ ned as either any soft drusen (distinct or indistinct) 
and pigmentary abnormalities or large soft drusen 
125 μm or more in diameter with a large drusen area 
(>500 μm diameter circle) or large soft indistinct drusen 
in the absence of signs of late-stage disease. Late age-
related macular degeneration was deﬁ ned as the presence 
of any of the following: geographic atrophy or pigment 
epithelial detachment, subretinal haemorrhage or visible 
subretinal new vessel, or subretinal ﬁ brous scar or laser 
treatment scar.
Statistical analysis
Because intrinsic diﬃ  culties exist when undertaking a 
meta-analysis of data from varied studies with diﬀ ering 
characteristics such as disease deﬁ nition, age dis-
tribution of the sample, and prevalence estimates 
stratiﬁ ed by age and sex versus single prevalence 
estimates, we constructed statistical models to best 
describe and ﬁ t our extracted data. Heterogeneity issues 
were addressed in our pooled meta-analysis using a 
hierarchical Bayesian approach to establish the 
worldwide prevalence of age-related macular 
degeneration. This approach models the hierarchical 
See Online for appendix
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structure of data extracted, taking into account the 
diﬀ erence in age distribution across the studies and the 
eﬀ ects of ethnicity, sex, and region, to ensure greater 
precision in prevalence estimates.
Meta-analyses can be described in a hierarchical 
Bayesian model. The number of people with age-related 
macular degeneration (yij) can be speciﬁ ed as binomially 
distributed: yij ~ Binomial(nij,pij), where nij is the total 
number of participants and pij is the prevalence of age-
related macular degeneration in ith the study of the jth 
category of the varying covariate (eg, each study might 
consist of more than one ethnicity).
In the Bayesian approach, prevalence pij is considered 
as a random variable (that has a probability density 
distribution) by contrast with a ﬁ xed unknown parameter 
(an unknown value) in the classical approach. Hence, the 
logit transformation of pij follows a normal distribution: 
logit(pij) = uij and uij ~ Normal(uij,σ²), where σ² = 1 / τ.
To investigate and account for the heterogeneity within 
and between studies, we modelled uij as a linear 
combination of covariates that varies across studies (ie, 
age, sex, ethnicity, and regions). Hence, our base model 
to pool the overall prevalence of age-related macular 
degeneration was: uij = β0 + β1 * agelij + β2 * ageuij + β3 * ageuij, 
where agelij and ageuij are the centred and standardised 
lower and upper bounds of the age group range for 
participants of each study and ageuiij is a right censoring 
indicator for studies with right-censored age range data 
for the upper bound (eg, 80 or more years). The lower 
bound of age range was centred to 45 years and the upper 
bound was 85 years, and then standardised by dividing 
by their respective standard deviations to ensure that 
pooled estimates were comparable since they were being 
mapped onto the same age range (45–85 years). Sex, 
ethnicity, and region covariates were then individually 
added to the base model to establish their eﬀ ect and for 
covariate-speciﬁ c pooled prevalence. The percentage of 
variability in prevalence estimates due to various sources 
of heterogeneity compared with chance alone were 
examined (appendix pp 1–3).
Finally, non-informative prior (to represent ignorance) 
was speciﬁ ed for residual variability τ using the 
conjugate gamma distribution: Gamma(0·01, 0·01). 
Gamma distribution is applicable to unknown 
quantities that take values between 0 and inﬁ nity. All 
age coeﬃ  cients and intercept in the model were 
speciﬁ ed with non-informative normal priors—ie, 
β~Normal(0, 0·0001).
The Gibbs sampler algorithm, an iterative Markov-
chain Monte Carlo technique, was used to estimate the 
posterior distributions of our random variables using the 
R and JAGS program.24,25 We used the JAGS software 
(version 3.3.0), running from R version 3.0.2 
(R Development Core Team, 2013) to implement the 
Gibbs sampler, using speciﬁ c marginal posterior 
densities.24,25 Convergence estimation was assessed by 
calculating the Gelman–Rubin convergence statistics.24,25
Ethnicity, region, and gender eﬀ ects
Bayesian hypothesis testing was done to examine the 
eﬀ ect of ethnicity, geographic regions, and sex on the 
prevalence of any, early, and late age-related macular 
degeneration. Bayes factors were used to compare 
hypotheses of diﬀ erences between groups, implementing 
the Gibbs variable selection as proposed by Dellaportas 
and colleagues26 using the JAGS software. The 
comparison of the posterior probabilities of hypothesis is 
given by: 
where H₀ is the null hypothesis and H₁ is the alternative 
hypothesis. Jeﬀ reys27 proposed an interpretation scheme 
for the magnitude of Bayes factors in terms of weak 
(1–3), substantial (3–10), strong (10–30), very strong 
(30–100), and decisive (>100) for H₁, whereas Bayes 
factors of less than 1 suggest support for the null 
hypothesis.
We assessed four major ethnic groups (European 
ancestry populations [Europeans], African ancestry 
populations [Africans], Asians, and Hispanics) and six 
geographic regions (Africa, Asia, Europe, Latin America 
and the Caribbean, northern America, and Oceania). 
Publication year was also tested to assess the trend of 
prevalence over the years for consideration in projection 
estimates.
Because the random eﬀ ect model is the most frequently 
used meta-analytical method to account for the 
heterogeneity between the studies by incorporating a 
random eﬀ ect estimate of between-study variation in the 
weighting, we did a simulation study to assess and 
compare the hierarchical Bayesian approach and the 
random eﬀ ect methods (appendix pp 1–3, 9).
Projection estimates
Model μijk = β0k + β1k * ageij + β2 * ageuiij + β3 * studyi was used 
to estimate the prevalence for each year increase in age 
for the kth region. Global and region eﬀ ects were 
incorporated as ﬁ xed and random eﬀ ects in β0k and β1k. 
Age-speciﬁ c prevalence was often reported as an interval 
(eg, 40–49 years) or censored (eg, 80 years or more) age 
range in the published papers, and hence the median of 
interval was used to represent the age interval, and 
censored age range was taken as the age with a censoring 
indicator in the analysis model. The estimated prevalence 
was used to calculate the global and region-speciﬁ c total 
number of individuals with age-related macular 
degeneration in 2020 and 2040 by multiplying the age-
speciﬁ c and region-speciﬁ c estimated prevalence rates to 
the UN World Population Prospects data.28 Age-group-
speciﬁ c prevalence rates were assumed to remain 
constant for our global projection to 2040, since Bayesian 
= ×
P(data|H1)
P(data|H0)
P(H1)
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odds) 
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Figure 1: Overall and race-speciﬁ ed pooled prevalence of early age-related macular degeneration (AMD)
Dashed line refers to the overall pooled prevalence estimate presented in bold. See appendix (p 7, 8) for study references.
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Figure 2: Overall and race-speciﬁ ed pooled prevalence of late age-related macular degeneration
Dashed line refers to the overall pooled prevalence estimate presented in bold.
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Figure 3: Overall and race-speciﬁ ed pooled prevalence of any age-related macular degeneration
Dashed line refers to the overall pooled prevalence estimate presented in bold.
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hypothesis testing of the publication year covariate in our 
review showed no trend for prevalence from 1989 to 2013.
Role of the funding source
The sponsors of this study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report, or in the decision to submit for 
publication. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication.
Results
2751 published original research articles, letters, 
abstracts, and review articles based on abstracts and titles 
were identiﬁ ed as of May, 2013, from our literature search 
(appendix pp 4–8). After initial abstract review, 
54 potentially eligible articles were retrieved for 
assessment. Of these, we applied the inclusion and 
exclusion criteria and identiﬁ ed 39 eligible articles 
reporting on 39 population-based studies (12 727 cases in 
129 664 participants and ﬁ ve ethnic ancestry groups; 
appendix pp 4–8). Data from patients with early, late, and 
any age-related macular degeneration were pooled 
separately. Of the study participants, 43·5% were of 
European ancestry, 12·4% were of African ancestry, 
33·1% were Asian, 9·7% Hispanic, and 1·3% other.
Figure 1–3 shows the overall and ethnic-speciﬁ c pooled 
prevalence of age-related macular degeneration. The lack 
of overlap in credible intervals from graphical inspection 
of forest plots suggests the presence of heterogeneity. 
Further analysis showed that heterogeneity in ethnicity 
and geographic regions for any stage were 99·5% 
(95% CrI 99·2–99·8) and 99·7% (99·5–99·9), 
respectively (appendix p 11). The pooled global 
prevalences (accounting for various sources of 
heterogeneity) of early and late-stage disease in adult 
populations were 8·01% (95% CrI 3·95–15·49) and 
0·37% (0·18–0·77), respectively. The overall prevalence 
of any age-related macular degeneration was 8·69% 
(95% CrI 4·26–17·40). Detailed estimated prevalence by 
subtypes, ethnicity, and age groups from meta-analysis 
using the hierarchical Bayesian approach are provided in 
the appendix (pp 12,13).
Early age-related macular degeneration was more 
prevalent in populations of European ancestry (11·2%) 
than in Asians (6·8%), with a Bayes factor of 3·9, 
suggesting substantial evidence for the diﬀ erence 
between groups (appendix p 10). Likewise, any age-
related macular degeneration was more prevalent in 
populations of European ancestry than Asian (12·3% vs 
7·4%; Bayes factor 4·3). Compared with African ancestry 
populations, people of European ancestry had higher 
prevalence of early, late, or any age-related macular 
degeneration (late: 12·3% vs 7·5%; Bayes factor 31·3, 
suggesting very strong evidence). Geographically, early 
and any disease were less prevalent in Asia than in 
Europe and northern America (all Bayes factors >2; 
ﬁ gure 4 and appendix p 10). There was no evidence of 
diﬀ erence in the prevalence of early, late, or any age-
related macular degeneration between sexes (all Bayes 
factors <0·05, appendix p 10). Eight (21%) of the 
39 studies provided information on geographic atrophy 
and neovascular subtypes. Subgroup analysis showed 
similar overall prevalence of geographic atrophy (0·44%, 
95% CrI 0·15–1·36) and neovascular age-related macular 
degeneration (0·46%, 0·18–1·08). Europeans had a 
higher prevalence of geographic atrophy (1·11%, 95% CrI 
0·53–2·08) than Africans (0·14%, 0·04–0·45), Asians 
(0·21%, 0·04–0·87), and Hispanics (0·16%, 0·05–0·46). 
There was no diﬀ erence in prevalence of neovascular 
age-related macular degeneration between ethnicities.
The prevalence of early and late disease increased with 
age in each of the ethnic groups and regions (ﬁ gure 5). 
Prevalence of late disease in populations with European 
ancestry increased most rapidly after age 75 years, with a 
similar trend seen in Europe and Oceania regions.
Figure 4: Prevalence of age-related macular degeneration (AMD) by ethnic group (A) and (B) geographical region
Error bars=95% CrI.
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The projected number of people with age-related 
macular degeneration by region in the years 2014, 2020, 
and 2040 are shown in ﬁ gure 6 and the appendix 
(pp 14–16). In the year 2020, global projected cases of any 
age-related macular degeneration are 196 million 
(95% CrI 140–261), rising to 288 million (205–399) in 
2040, with the largest number of cases in Asia (113 million 
[60–203] in 2040). Europe is expected to be second to Asia 
in the number of projected cases (69 million [40–109] in 
2040), followed by Africa (39 million [12–93]), Latin 
America and the Caribbean (39 million [15–82]), North 
America (25 million [15–38]), and Oceania (2 million 
[1–5]). Pairwise comparison between geographical 
regions showed statistical evidence for the larger 
projected number of people with any age-related macular 
degeneration in 2040 in Asia compared with Latin 
America and the Caribbean, northern America, and 
Oceania, and up to 2038 for Africa (appendix pp 17,18).
Discussion
This systematic review and meta-analysis has shown that 
8·7% of the worldwide population has age-related 
macular degeneration, and the projected number of 
people with the disease is around 196 million in 2020, 
increasing to 288 million in 2040. We found substantial 
evidence that early age-related macular degeneration was 
more prevalent in Europe than in Asia, but that rates of 
late onset were similar. These results conﬁ rm those of 
previous meta-analyses4 and multiethnic population-
based studies.15 Asian (Chinese) people might be more 
Figure 5: Age trends of prevalence of age-related macular degeneration (AMD) by ethnicity (A and B) and region (C and D)
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likely to develop exudative or neovascular age-related 
macular degeneration than white people,15,29 but our 
subgroup analysis suggests no evidence for ethnicity 
diﬀ erence. Also, most population-based studies were 
unable to reliably diagnose polypoidal choroidal 
vasculopathy, which often manifests like exudative age-
related macular degeneration. Taking into consideration 
that polypoidal choroidal vasculopathy is markedly more 
common in Asians than in Europeans, we could be 
overestimating the true prevalence of late disease in 
Asians.30–32 Our study also provides strong evidence that 
early, late, and any age-related macular degeneration is 
more prevalent in people of European ancestry than 
those of African ancestry, which validates observations 
derived from previous individual studies, such as the 
Baltimore Eye Study.15,16 These patterns are in line with a 
previous multiethnic population-based study in the USA, 
whereby the prevalence of early disease was highest in 
people of European ancestry, compared with Hispanics, 
Asians (Chinese), and African Americans.15
Our meta-analysis updates two earlier reviews focused 
on single ethnicities, one in Europeans by Rudnicka and 
colleagues17 and one in Asians by Kawasaki and 
colleagues.4 In our study, compared with the Asian meta-
analysis, we included four additional Asian studies 
published after 2010, including the Handan Eye 
Study,33 the Central India Eye and Medical Study,34 one 
multiethnic Asian cohort study in Singapore,35 and one 
study in Thailand.36 Unlike Rudnicka and colleagues, six 
studies published between 1970 and 1990 were excluded 
since they relied only on eye examinations, without taking 
fundus photos, and used study-speciﬁ c deﬁ nitions.29,37–41 We 
included only participants with internationally recog-
nised deﬁ nitions of age-related macular degen-
eration21,22 conﬁ rmed using retinal photographs.
Analysis of pooled prevalence by geographical regions 
showed greater variability, indicated by the larger 95% 
credible intervals compared with prevalence pooled by 
ethnic ancestry groups. This ﬁ nding could be due to 
heterogeneity contributed by various ethnic groups 
within each region, and lends further support to the 
hypothesis that inherited genetic factors determined by 
ethnic ancestry play a substantial part in age-related 
macular degeneration,42–44 in addition to established 
environmental risk factors such as smoking. Northern 
America and Europe had a higher pooled prevalence of 
early and any age-related macular degeneration than in 
Asia, in accordance with the higher prevalence in people 
of European ancestry than in Asians, as reported both in 
the literature and substantiated in our meta-analysis.
Female gender was considered a weak risk factor, with 
inconsistent association for late age-related macular 
degeneration.45,46 In our meta-analysis, there was no 
evidence of gender diﬀ erence in both early and late 
prevalence. This ﬁ nding is consistent with previous 
reviews in people of European ancestry, where no 
signiﬁ cant gender diﬀ erence was found in the prevalence 
of neovascular age-related macular degeneration or 
geographic atrophy.47 Similarly in Asians, men do not 
have a higher prevalence of late disease than women 
after adjusting for risk factors such as smoking.48–50
Figure 6: Projection of number of people with early and late age-related 
macular degeneration (AMD) by regions in 2014, 2020, and 2040
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Asia accounts for more than 60% of the world population 
and hence will see the largest projected number of cases 
of age-related macular degeneration (a third of the cases 
globally), and is expected to increase more rapidly than 
other regions over the years, despite having the lowest 
estimated prevalence currently. Europe, being the third 
most populous region (11%) with the highest prevalence 
of age-related macular degeneration, follows after Asia in 
the number of projected cases, with a moderate increase 
over the years. The trends and diﬀ erences between regions 
are mainly aﬀ ected by the demographic progression in 
population structure (ie, an ageing population) of the 
regions based on UN population projection data.28 These 
ﬁ ndings are important, since more than two-thirds of 
aﬀ ected patients in Asia, Africa, and Latin America might 
not have access to expensive anti-angiogenesis therapies 
now widely used in North America and Europe.
The strength of our study is that we pooled data that 
used fundus photography and standardised protocols to 
assess age-related macular degeneration. Our study was 
limited by the fact that, despite the large number of studies 
included in this meta-analysis, our subgroup analysis on 
the prevalence of late disease subtypes (ie, neovascular age-
related macular degeneration vs geographic atrophy) by 
ethnicity used data from only eight studies. Moreover, 
there is evidence that without harmonisation of class-
iﬁ cation systems and deﬁ nitions of lesions, estimates of 
early age-related macular degeneration might sub stantially 
vary due to several factors. These include varying 
deﬁ nitions used for grading the disease and inconsistencies 
in quality of images.51 Although there are inherent 
disadvantages in undertaking a meta-analysis based on 
datasets pooled together from disparate population 
studies, we have attempted to circumvent this issue by 
only including studies in which standard protocols are 
used to grade fundus photos.
There is substantial evidence for higher prevalence of 
early disease in people of European ancestry than in 
Asians, and early and late disease in people of European 
ancestry than in those of African ancestry. We noted that 
late prevalence increases rapidly after age 75 years, 
especially in people of European ethnicity and in Europe 
and Oceania regions, but Asia will see the largest number 
of people with the condition despite currently having the 
lowest prevalence. These data provide important infor-
mation for the design and implementation of eye care 
programmes for both speciﬁ c ethnic groups and 
geographical regions, as well as worldwide.
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